HealthCor Partners Management LP - 07 Aug 2025 Form 3 Insider Report for Heartflow, Inc. (HTFL)

Role
10%+ Owner
Signature
HealthCor Partners Management, L.P., by HealthCor Partners GP, LLC, general partner, by /s/ Jeffrey C. Lightcap, Senior Managing Director
Issuer symbol
HTFL
Transactions as of
07 Aug 2025
Transactions value $
$0
Form type
3
Date filed
22 Aug 2025, 17:13
Next filing
22 Aug 2025
SEC
View on sec.gov

Reporting Owners (7)

Name Relationship Address Signature Signature date CIK
HealthCor Partners Management LP 10%+ Owner 186 SEVEN FARMS DRIVE, SUITE F-371, DANIEL ISLAND HealthCor Partners Management, L.P., by HealthCor Partners GP, LLC, general partner, by /s/ Jeffrey C. Lightcap, Senior Managing Director 2025-08-22 0001519462
HealthCor Partners Fund LP 10%+ Owner 186 SEVEN FARMS DRIVE, SUITE F-371, DANIEL ISLAND HealthCor Partners Fund, L.P., by HealthCor Partners, L.P., general partner, by HealthCor Partners GP, LLC, its General Partner, by /s/ Jeffrey C. Lightcap, Senior Managing Director 2025-08-22 0001408660
HealthCor Partners LP 10%+ Owner 186 SEVEN FARMS DRIVE, SUITE F-371, DANIEL ISLAND HealthCor Partners, L.P., by HealthCor Partners GP, LLC, general partner, by /s/ Jeffrey C. Lightcap, Senior Managing Director 2025-08-22 0001519456
HealthCor Partners GP, LLC 10%+ Owner 186 SEVEN FARMS DRIVE, SUITE F-371, DANIEL ISLAND HealthCor Partners GP, LLC, by /s/ Jeffrey C. Lightcap, Senior Managing Director 2025-08-22 0001519460
HealthCor Partners Fund II, L.P. 10%+ Owner 186 SEVEN FARMS DRIVE, SUITE F-371, DANIEL ISLAND HealthCor Partners Fund II, L.P., by HealthCor Partners II, L.P., general partner, by HealthCor Partners GP, LLC, its general partner, by /s/ Jeffrey C. Lightcap, Senior Managing Director 2025-08-22 0001538581
HealthCor Partners II, L.P. 10%+ Owner 186 SEVEN FARMS DRIVE, SUITE F-371, DANIEL ISLAND HealthCor Partners II, L.P., by HealthCor Partners GP, LLC, its general partner, by /s/ Jeffrey C. Lightcap, Senior Managing Director 2025-08-22 0001643094
HCPCIV 1, LLC 10%+ Owner 186 SEVEN FARMS DRIVE, SUITE F-371, DANIEL ISLAND HCPCIV 1, LLC, by HealthCor Partners II, L.P., its managing member, by HealthCor Partners GP, LLC, its general partner, by /s/ Jeffrey C. Lightcap, Senior Managing Director 2025-08-22 0002083103

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding HTFL Series C Preferred 07 Aug 2025 Common Stock 1.25M By HealthCor Partners Fund, L.P. F1, F2, F9
holding HTFL Series C Preferred 07 Aug 2025 Common Stock 624K By HealthCor Partners Fund II, L.P. F1, F3, F9
holding HTFL Series D Preferred 07 Aug 2025 Common Stock 1.63M By HCPCIV I, LLC F4, F5, F9
holding HTFL Series D Preferred 07 Aug 2025 Common Stock 209K By HealthCor Partners Fund II, L.P. F3, F4, F9
holding HTFL Series E Preferred Stock 07 Aug 2025 Common Stock 1.1M By HCPCIV I, LLC F5, F6, F9
holding HTFL Series F Preferred Stock 07 Aug 2025 Common Stock 1.34M By HCPCIV I, LLC F5, F7, F9
holding HTFL Series F-1 Preferred Stock 07 Aug 2025 Common Stock 453K By HCPCIV I, LLC F5, F7, F9
holding HTFL Convertible Promissory Note 07 Aug 2025 Common Stock $1.46M By HCPCIV I, LLC F5, F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series C preferred stock is convertible on a 1 to 0.5764 basis into shares of Heartflow, Inc.'s ("Heartflow") common stock and has no expiration date. The Series C preferred stock will automatically convert into the underlying shares of common stock upon the closing of Heartflow's initial public offering. The conversion rate gives effect to the 1 for 2.92 reverse stock split of Heartflow's common stock, which became effective on July 31, 2025.
F2 HealthCor Partners Fund, L.P. ("HCP Fund") is a private investment partnership which is the direct beneficial owner of the securities reported herein. The shares held by HCP Fund may be deemed to be beneficially owned by HealthCor Partners L.P. ("HCPLP"), its general partner, and by HealthCor Partners GP, LLC ("HCPGP"), the general partner of HCPLP. Each of HCPLP and HCPGP hereby disclaims any beneficial ownership of shares held by HCP Fund except to the extent of any pecuniary interest therein.
F3 HealthCor Partners Fund II, L.P. ("HCPII Fund") is a private investment partnership which is the direct beneficial owner of the securities reported herein. The shares held by HCPII Fund may be deemed to be beneficially owned by HealthCor Partners II, L.P. ("HCP2LP"), its general partner, and by HCPGP, the general partner of HCP2LP. Each of HCP2LP and HCPGP hereby disclaims any beneficial ownership of shares held by HCPII Fund except to the extent of any pecuniary interest therein.
F4 Each share of Series D preferred stock is convertible on a 1 to 0.6467 basis into shares of Heartflow's common stock and has no expiration date. The Series D preferred stock will automatically convert into the underlying shares of common stock upon the closing of Heartflow's initial public offering. The conversion rate gives effect to the 1 for 2.92 reverse stock split of Heartflow's common stock, which became effective on July 31, 2025.
F5 HCPCIV 1, LLC ("HCPCIV") is a private investment limited liability company which is the direct beneficial owner of the securities reported herein. The shares held by HCPCIV may be determined to be beneficially owned by HCP2LP, its managing member, and by HCPGP. Each of HCP2LP and HCPGP hereby disclaims any beneficial ownership of shares held by HCPCIV except to the extent of any pecuniary interest therein.
F6 Each share of Series E preferred stock is convertible on a 1 to 0.6951 basis into shares of Heartflow's common stock and has no expiration date. The Series E preferred stock will automatically convert into the underlying shares of common stock upon the closing of Heartflow's initial public offering. The conversion rate gives effect to the 1 for 2.92 reverse stock split of Heartflow's common stock, which became effective on July 31, 2025.
F7 Each share of Series F preferred stock and Series F-1 preferred stock is convertible on a 1 to 0.3425 basis into shares of Heartflow's common stock and has no expiration date. The Series F preferred stock and Series F-1 preferred stock will automatically convert into the underlying shares of common stock upon the closing of Heartflow's initial public offering. The conversion rate gives effect to the 1 for 2.92 reverse stock split of Heartflow's common stock, which became effective on July 31, 2025.
F8 Represents the outstanding principal amount of a convertible promissory note held by HCPCIV 1, LLC, which will automatically convert upon the consummation of Heartflow's initial public offering into shares of common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. These shares of common stock issuable upon conversion of the convertible promissory note have no expiration date.
F9 HealthCor Partners Management, L.P. is the investment manager for each of HCP Fund, HCPH Fund, and HCPCIV and has voting and investment discretion with respect to such entities' securities reported herein. HealthCor Partners Management, L.P. hereby disclaims any beneficial ownership of shares held by HCP Fund, HCPH Fund, and HCPCIV except to the extent of any pecuniary interest therein.